X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs MERCK LTD - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA MERCK LTD AUROBINDO PHARMA/
MERCK LTD
 
P/E (TTM) x 16.0 35.2 45.5% View Chart
P/BV x 4.1 3.9 104.3% View Chart
Dividend Yield % 0.4 0.7 52.9%  

Financials

 AUROBINDO PHARMA   MERCK LTD
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
MERCK LTD
Dec-16
AUROBINDO PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs8951,060 84.4%   
Low Rs622623 99.8%   
Sales per share (Unadj.) Rs254.6632.4 40.3%  
Earnings per share (Unadj.) Rs39.345.7 85.9%  
Cash flow per share (Unadj.) Rs46.662.3 74.7%  
Dividends per share (Unadj.) Rs2.5011.00 22.7%  
Dividend yield (eoy) %0.31.3 25.2%  
Book value per share (Unadj.) Rs160.0388.8 41.1%  
Shares outstanding (eoy) m585.8816.60 3,529.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.3 223.9%   
Avg P/E ratio x19.318.4 104.9%  
P/CF ratio (eoy) x16.313.5 120.6%  
Price / Book Value ratio x4.72.2 219.1%  
Dividend payout %6.424.1 26.5%   
Avg Mkt Cap Rs m444,39013,969 3,181.3%   
No. of employees `00014.01.6 883.3%   
Total wages/salary Rs m17,6781,487 1,189.0%   
Avg. sales/employee Rs Th10,667.86,631.9 160.9%   
Avg. wages/employee Rs Th1,264.3939.2 134.6%   
Avg. net profit/employee Rs Th1,645.8479.4 343.3%   
INCOME DATA
Net Sales Rs m149,15710,498 1,420.8%  
Other income Rs m1,159242 478.1%   
Total revenues Rs m150,31610,741 1,399.5%   
Gross profit Rs m34,3431,135 3,025.0%  
Depreciation Rs m4,276276 1,552.2%   
Interest Rs m6670-   
Profit before tax Rs m30,5581,102 2,772.5%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,597343 2,212.8%   
Profit after tax Rs m23,012759 3,032.3%  
Gross profit margin %23.010.8 212.9%  
Effective tax rate %24.931.1 79.8%   
Net profit margin %15.47.2 213.4%  
BALANCE SHEET DATA
Current assets Rs m92,0626,410 1,436.3%   
Current liabilities Rs m66,2238,828 750.1%   
Net working cap to sales %17.3-23.0 -75.2%  
Current ratio x1.40.7 191.5%  
Inventory Days Days10658 183.7%  
Debtors Days Days6838 176.3%  
Net fixed assets Rs m62,9191,406 4,473.7%   
Share capital Rs m586166 353.0%   
"Free" reserves Rs m93,1336,286 1,481.6%   
Net worth Rs m93,7196,455 1,452.0%   
Long term debt Rs m1,8140-   
Total assets Rs m162,4948,828 1,840.6%  
Interest coverage x46.8NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.91.2 77.2%   
Return on assets %14.68.6 169.5%  
Return on equity %24.611.8 208.8%  
Return on capital %32.717.1 191.7%  
Exports to sales %08.3 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs mNA2,209 0.0%   
Fx inflow Rs m75,838959 7,909.6%   
Fx outflow Rs m30,2242,612 1,157.1%   
Net fx Rs m45,613-1,653 -2,759.1%   
CASH FLOW
From Operations Rs m32,7861,070 3,062.9%  
From Investments Rs m-17,870-750 2,383.7%  
From Financial Activity Rs m-19,153-150 12,785.4%  
Net Cashflow Rs m-4,239171 -2,480.2%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 8.0 18.2 43.7%  
FIIs % 27.7 1.0 2,770.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 29.1 35.1%  
Shareholders   69,601 28,591 243.4%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   IPCA LABS  NOVARTIS  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Strong; Infosys & Axis Bank Top Gainers(01:30 pm)

After opening the day in green, the Indian share markets have continued the momentum and are presently trading on a strong note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 17, 2018 03:03 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS